All Q1 FY27 results →

KA

KRM Ayurveda Ltd

Q1 FY27

KRM Ayurveda Q1 FY27: Revenue ₹25 Cr, EBITDA margin 38.22%

Q1 FY27 investor presentation: what the company reported on revenue, margins and projects.

Price₹266

Market cap₹564 Cr

P/E22.4

Updated16 Oct 2026

Read4 min read

Based on KRM Ayurveda Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

The short version

Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY - Revenue from operations: ₹3,232.26 Lakhs, +31.0% YoY - EBITDA for Q1 FY27: ₹1,256.07 Lakhs, +97.4% YoY - Net profit (PAT) for Q1 FY27: ₹90 EBITDA for Q1 FY27: ₹1,256.07 lakhs - Year-on-year growth: +97.4% - EBITDA margin: 38.22% (+1,257 bps YoY, +372 bps QoQ) - Profit After Tax (PAT) for Q1 FY27: ₹908.45 lakhs - Year

From KRM Ayurveda Ltd's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY
Revenue from operations: ₹3,232.26 Lakhs, +31.0% YoY
EBITDA for Q1 FY27: ₹1,256.07 Lakhs, +97.4% YoY
Net profit (PAT) for Q1 FY27: ₹908.45 Lakhs, +124.2% YoY
Product revenue quarterly trend: ₹1,579 Lakhs in Q1 FY27, broadly stable vs ₹4,701 Lakhs FY26 (vs ₹4,923 Lakhs FY25)
Services revenue Q1 FY27: ₹2,392.20 Lakhs, +109.8% YoY
FY26 Services revenue doubled vs FY25 (+100.2%) at ₹5,468 Lakhs

2 more points from KRM Ayurveda Ltd's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

EBITDA for Q1 FY27: ₹1,256.07 lakhs
Year-on-year growth: +97.4%
EBITDA margin: 38.22% (+1,257 bps YoY, +372 bps QoQ)
Profit After Tax (PAT) for Q1 FY27: ₹908.45 lakhs
Year-on-year growth: +124.2%
PAT margin: 27.64% (+1,131 bps YoY, +354 bps QoQ)

2 more points from KRM Ayurveda Ltd's call on margins

Pro opens every point from 15K+ earnings calls

See what KRM Ayurveda Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capacity Expansion:
Addition of 103 incremental beds in FY27 to existing hospital facilities.
Incremental annualized IPD revenue potential from these beds: ~Rs. 25 crore.
New Plant/Project:
In-house manufacturing facility at Kundli, Haryana supporting scale-up.
Owned D2C e-commerce platform scheduled to go live in Q2 FY27.
Platform will support OTC & D2C product range (capsules, tablets, syrups, oils).
Marketplaces listings planned on 1mg and other leading national platforms in Q2 FY27.

2 more points from KRM Ayurveda Ltd's call on capex

Pro opens every point from 15K+ earnings calls

Fundraising & Capital Structure

The investor presentation does not mention any fundraising through debt or equity, nor does it indicate any change in borrowings or net debt. Specifically: - There is no reference to issuance of new equity or debt instruments. - No details on changes in borrowings or net debt figures are provided.

- The financial data focuses on income, revenue, profitability, margins, and operational metrics like beds added. - The presentation highlights growth in EBITDA, PAT, revenue, and product launch plans but omits any notes on capital raising or financing activities. All figures and commentary pertain solely to operational and financial performance without disclosure of any fundraising or changes in debt.

2 more points from KRM Ayurveda Ltd's call on fundraising

Pro opens every point from 15K+ earnings calls

See what KRM Ayurveda Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation does not explicitly report any figures or details regarding order book, order inflow, or pending orders. Specifically: - There is no mention of order book size or value anywhere in the five pages. - No data or commentary on order inflow rates or recent orders received is provided. - Pending orders or backlog information is not presented.

2 more points from KRM Ayurveda Ltd's call on order book

Pro opens every point from 15K+ earnings calls

What KRM Ayurveda's management said in earlier quarters

Q4 FY26 earnings call analysis →

Others in Pharmaceuticals & Biotechnology this season

Trident Lifeline (Q1 FY27)
Q1 FY26: ₹23.6 crores . Key investor presentation takeaways from Trident Lifeline Ltd's Q1 FY27 investor presentation — and how it ranks against sector peers.
Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

KRM Ayurveda Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were KRM Ayurveda Ltd Q1 FY27 results?

Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY - Revenue from operations: ₹3,232.26 Lakhs, +31.0% YoY - EBITDA for Q1 FY27: ₹1,256.07 Lakhs, +97.4% YoY - Net profit (PAT) for Q1 FY27: ₹90 EBITDA for Q1 FY27: ₹1,256.07 lakhs - Year-on-year growth: +97.4% - EBITDA margin: 38.22% (+1,257 bps YoY, +372 bps QoQ) - Profit After Tax (PAT) for Q1 FY27: ₹908.45 lakhs - Year

What is KRM Ayurveda Ltd share price analysis?

KRM Ayurveda Ltd currently shows a neutral. The stock trades at a P/E of 22.4 with a market cap of ₹564 Cr. Investors should review the full earnings analysis for detailed insights.

Is KRM Ayurveda Ltd planning capital expenditure?

Capacity Expansion: - Addition of 103 incremental beds in FY27 to existing hospital facilities. - Incremental annualized IPD revenue potential from these beds: ~Rs.

Keep KRM Ayurveda Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.